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We used a nontransgenic cellular tauopathy model in which individual giant neurons in the lamprey CNS (ABCs) overexpress
human tau isoforms cell autonomously to characterize the still poorly understood consequences of disease-associated tau
processingin situ. In this model,taucolocalizes with endogenousmicrotubules andis nontoxicwhen expressed atlowlevels,but is
misprocessedbyatoxicity-associatedalternativepathwaywhenexpressedabovelevelsthatsaturatedendriticmicrotubules,causing
abnormally phosphorylated, vesicle-associated tau to accumulate in ABC distal dendrites. This causes localized microtubule loss
and eventually dendritic degeneration, which is preceded by tau secretion to the extracellular space. This sequence is reiterated
at successively more proximal dendritic locations over time, suggesting that tau-induced dendritic degeneration is driven by
distal dendritic accumulation of hyperphosphorylated, vesicle-associated tau perpetuated by localized microtubule loss. The
implications for the diagnosis and treatment of human disease are discussed.
1.Introduction
Alterationsofthe microtubule-associated protein(MAP) tau
that aﬀect tau:tau and tau:tubulin interactions are a key fac-
tor in the cytopathogenesis of neurodegenerative syndromes
involving tau (tauopathies) [1–3]r e v i e w e di n[ 4, 5]. Phos-
phorylation at proline-directed sites ﬂanking the micro-
tubule binding repeat (MTBR) domain is inhibitory to MT
binding, and ultimately causes the formation of tau aggre-
gates [6] and progressive loss of MTs and neurodegeneration
in tauopathy models [7–12]. The extent to which this occurs
is likely a keydeterminant of whether tau is playing a normal
or pathological role [4, 13]. Exonic tau mutations respon-
sible for familial tauopathies cause hyperphosphorylation,
a reduction in MT binding, and an increased tendency to
aggregate [14–17], suggesting that a causal link exists be-
tween these features and toxicity. Although mutant tau iso-
forms are more toxic than wild-type (WT) isoforms when
expressed in situ [7], the patterns of degeneration produced
by WT and mutant tau species are very similar, even in
disease models using identiﬁed neurons [18], suggesting that
thecytoplasmicaccumulationofhyperphosphorylated, non-
MT-bound tau is a common feature that drives toxicity.
Since the tau MTBR forms the core of the neuroﬁbrillary
aggregates characteristic of tauopathies and is the site of
most exonic mutations that drive familial tauopathies [6,
19, 20], the modulation of tau:MT and tau:tau interactions
via tau phosphorylation [1, 3, 13, 21]o rc l e a v a g e[ 22–25]
to form toxic oligomers or aggregates [26]h a sb e c o m et h e
central research focus in studies of tau-induced toxicity and
tauopathy cytopathogenesis. However, very little is known
abouthowtauaggregatesareproducedanddistributedinthe
somata and dendrites of neurons in situ, making it diﬃcult
to establish the sequence and causality of cellular events
that lead to neurodegeneration. The role of aggregation is
further obscured by ﬁndings that cleavage fragments of the
amino terminal “projection” domain of tau [27–30] can also
mediate tau toxicity via a separate pathway [30, 31]. This
pathway involves caspase [32]a n dc a l p a i n[ 33]a c t i v a t i o n
and can mediate toxicity caused by extracellular agents, such2 International Journal of Alzheimer’s Disease
as beta amyloid [34]· We now know that tau misprocessing
also involves the interaction of tau with lipid raft-associated
proteins at the plasma membrane via the tau N-terminal
domain [35, 36], which becomes phosphorylated at tyrosine
18 (Y18) [37]. Abnormal tau-actin interactions [38]a n dt h e
misrouting of tau to the Golgi [39] in tauopathy suggest that
an abnormal association with the plasma membrane and/or
“traﬃcking” vesicles derived from it may also play a role in
tau-mediated toxicity. Recent ﬁndings that tau is secreted
to [40, 41]a n dt a k e nu pf r o m[ 42] the extracellular space
and that it can be transported transneuronally in situ [40,
43] make it necessary to distinguish cell autonomous from
interneuronal eﬀects of tau misprocessing. In this study, we
used the unique advantages of the lamprey ABC tauopathy
model, in which tau is expressed cell autonomously in
identiﬁed neurons (ABCs),to characterize tau misprocessing
at the cellular level in neurodegeneration in situ.
We use confocalmicroscopy and thehigh spatiotemporal
resolution oﬀered by the ABC tauopathy model to make a
detailed correlation between the expression level, intracel-
lular distribution, phosphorylation state, and secretion of
human tau isoforms relative to the distribution and stability
of MTs. We previously used this model to show that tau
phosphorylated at Y18 (9G3+ tau) becomes associated with
vesicle-like particles and accumulates in ABC dendritic tips
[18, 41], where it causes distension and ultimately degen-
eration [8, 9, 18, 41]. In this study, we address the role(s)
played by (a) tau-MT binding (and the phosphorylation of
sites known to aﬀect tau:MT binding) and (b) the eﬀects
of tau expression level and somatodendritic distribution in
producing the toxic eﬀects caused by tau expression on the
neuronal cytoskeleton in situ. We show that exogenous tau
expression above the level needed to saturate dendritic MTs
results in the redistribution of speciﬁc phosphotau species
(9G3/12E8 tau) distally to dendritic tips, dendritic MT loss
in the vicinity of tau accumulation, and tau secretion from
tau accumulation sites with ongoing or recent MT loss. In
addition, we characterized the morphology of exocytosing
vesicles involved in tau secretion and identiﬁed proteins that
colocalize with tau as it is secreted. We propose that non-
MT-associated tau accumulation activates an alternative tau
processing pathway involving abnormal endosome forma-
tion,centrifugal dendritictransport, and secretionofvesicle-
associated tau and suggest that this may play a key role in the
cellularandintercellularpathogenesisofhuman tauopathies.
2.Methods
2.1. Tau Expression. We used the pEn123c and pEn1234c
plasmids encoding green ﬂuorescent protein-(GFP-) tagged
wild-type human tau 3R0N and 4R0N isoforms (resp.) for
most of these experiments. We also used P301L tauopathy
mutant of 4R0N and a double pseudophosphorylation mu-
tant at S262D and S356D in the MTBR of 3R0N that were
derived from the corresponding parent WT plasmids [18,
41].Plasmids encodinglampreyneuroﬁlament (NF180)[44]
or GFP [45] served as expression controls. All plasmids used
the CMV promoter to drive exogenous protein expression.
Microinjection of plasmids was performed as described [8],
using 1mg/mL of plasmid mixed in microtubule stabilizing
buﬀer.
2.2. Immunochemistry. Immunohistochemical analysis of
transverse sections through ABC somata, dendrites, and
axons (Figure 1) was performed using standard enzyme-
linked and immunoﬂuorescence protocols [8, 18, 41, 47,
48]. After 10 days following plasmid injection, brains were
reexposed under ﬂuorescence to identify ABCs expressing
GFP-tagged exogenous proteins and then ﬁxed with FAA
(10% formalin, 10% glacial acetic acid, and 80% ethanol),
dehydrated, embedded in paraﬃn, and sectioned at 10μm.
Rabbitpolyclonalanti-GFP (1:200,Invitrogen) were used to
detect the expression of GFP-tagged tau or NF-180. HRP-
linked staining with diaminobenzidine (Sigma) was used
on every 7th section to reveal immunopositive ABCs, with
the remaining sections used for immunoﬂuorescence. Sec-
tions were deparaﬃnized, rehydrated, quenched with H2O2,
boiled for 10min in pH 9 and 10mM Tris-EDTA buﬀer
to unmask antigen, and incubated in primary antibody
overnight at 4◦C. For immunoﬂuorescence staining, sections
were quenched 10 minutes in 1% sodium borohydride/TBS.
2.3. Antibodies. We used the following primary antibodies:
PHF1 (1:200), Tau1 (1:400), Tau5 (1:400), Tau7 (1:400),
Tau12 (1:400), Tau46 (1:100, Sigma), 9G3 (1:30), AT180
(1:200, Pierce), DM1A (1:500, Sigma), TUB1 (1:500,
Sigma), and 611B (1:500, Sigma). Tau1, Tau5, Tau7, and
Tau12 antibodies were kindly provided by Dr. Lester Binder
(Department of Cell and Molecular Biology, Northwestern
University Medical School, Chicago, IL, USA). PHF1 was a
generous gift from Dr. Peter Davies (Department of Pathol-
ogy, Albert Einstein of College of Medicine, Bronx, NY,
USA). 9G3 was provided by Dr. Gloria Lee (University of
Iowa, Iowa City, IA). Polyclonal Abs against human fyn
(1:50, Santa Cruz), LC3 (1:30, Abgent), and COX1 (1:200,
MitoScience) were used to label the highly conserved epony-
mous lamprey homologues of fyn (92% identity), LC3 (73%
identity), and COX1 (64% identity).
2.4. Data Analysis. Immunoﬂuorescence intensity was mea-
sured in multiply immunolabeled sections containing soma-
todendriticproﬁlesoftau-expressing ABCs.Confocalimages
were analyzed using either ImageJ or Volocity (ImproVi-
sion) to generate image stacks. In some cases, densitomet-
ric analysis of nonconfocal images of DAB-revealed adjacent
sections from the same brain was performed. For quantita-
tive assessment of exogenous tau immunolabel intensity or
for comparisons between diﬀerent phosphotau epitopes, the
immunolabel density at the point of dendritic degeneration
(POD) was normalized to 100%, with localization along
dendrites deﬁned in terms of distances from the POD (dis-
tal = plus). For the calculation of tau:tubulin intensity ratios
and for comparing “absolute” levels of tau expression (e.g.,
to assign ABCs to “low” and “high” tau expression catego-
ries), we compared tau (GFP tag) versus tubulin (DM1A)
immunolabel intensities in confocal stacks of multiply im-
munostained sections, which were scored relative to DM1AInternational Journal of Alzheimer’s Disease 3
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Figure 1: ABC morphology. (a) shows a confocal micrograph of a wholemounted lamprey brain with an ABC expressing low levels of
human tau and showing its characteristic gross morphology. Note that tau (red channel) is evenly codistributed with tubulin (DM1A-green
channel), resulting in a yellow appearance. Tubulin immunolabel in axons from large reticulospinal neurons other than ABCs (RSpA) can
be seen in whole mount (a) and in cross-section (c), and a Mauthner’s cell lateral dendrite can be seen in the whole-mounted preparation
(MthD).(b) Dorsal view ofa live lamprey brain with a pair ofABCs expressing exogenous GFP-tagged protein. Ten-micron-thick transverse
paraﬃnsections were takenthrough the somaand dendritic ﬁelds oftau-expressing ABCs (upper line) and though ABC axons in the caudal
hindbrain near the obex (b, bottom line). (c) Somatodendritic section through an ABC expressing low levels of Tau24 (4R0N tau). Both
the whole- mount in (a) and the top section shown in (c) were immunostained with the mAb DM1A for total alpha-tubulin and anti-GFP
for total exogenous tau. The bottom image is of a transverse section though ABC axons in the caudal hindbrain near the obex (at the level
indicated in (b), bottom line). Scale bars: (a) 100μm, (b) 200μm( c )5 0μm.
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Figure 2: Somatodendritic cytoskeletal elements in ABCs. (a) Somatodendritic and axonal distribution of cytoskeletal elements in ABCs
are shown in transverse sections through ABC somata and dendrites immunostained for total, dynamic, and stably polymerized tubulin
with axonal proﬁles shown in insets (top). The distributions of the major neuroﬁlament protein NF180, a tau-like endogenous MAP, and
a mitochondrial marker (COX1) are similarly displayed (bottom). MTs are the dominant dendritic element (especially tyrosinated tubulin-
rich MTs in largeproximaldendrites), whereas acetylated MTs andNFs predominate in the axon.An endogenous,axonallylocalized tau-like
proteinoccurs insea lampreys,butispoorly expressed inABCs.(b) Mitochondria aretypicallydistributed evenlythroughoutABCdendrites
and are somewhat more concentrated in axonal proﬁles (inset). Scale bars: (a) 100μm, (b) 50μm, (b) inset 10μm.
neuropil immunolabel in that location of the section using
the same PMT settings. Intensity of tubulin (DMIA, TUB1,
611b) immunolabel was scored relative to the neuropil sur-
rounding ABC axonal, dendritic, and somatic proﬁles. The
cellular elements of “neuropil” consist mainly of small axon
cross/longitudinal proﬁles that stain relatively uniformly for
the probes shown in Figure 2 and are unaﬀected by exoge-
nous protein expression in ABCs. All comparisons of im-
munolabel intensity were done using a two-sample t-test or
one-way ANOVA as appropriate; such data are expressed as
mean ± SEM, and signiﬁcance was expressed at P values as
noted. Quantitative analyses that required the categorization4 International Journal of Alzheimer’s Disease
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Figure 3:The intracellular distribution ofexogenous humantau versus controls.(a) Somatodendriticsections through ABCs expressing tau
(top) andanexpression controlGFP (bottom)showingtheselective axonal(asterisk)anddistaldendritic distribution (arrows)oftauversus
the relatively even distribution of exogenous protein. (b) Tau immunolabel is somewhat more concentrated in the proximal axon than in
proximal dendrites in low expressing ABCs. However, any selective localizationto the axon (asterisk) is slight and appears to be lost entirely
when normalized to MT immunolabel. (c) Examples of double-labeled sections through the somata and dendrites of ABCs exhibiting low
(left) and high (left center) tau expression illustrate the characteristic changes in tau distribution with expression level and their relationship
with dendritic beading and MT distribution relative to NF-180 expression controls. Tau (red) and tubulin (green) are colocalized in the
proximaldendrites of low expressing cells (asterisk),but tau immunolabelbecomes signiﬁcantlymoredistally located than thatoftubulin in
ABCs expressing higher tau levels (right, double asterisks). Note that the expression controls do not aﬀect MT distribution when NF-180 is
expressed in ABCs (right panels). (d) Human tau expression appear to “bundle” endogenous MTs (compare green channel label at arrows),
even when tau expression is above MT saturation,unlike the situation with dendrites. Scale bars: 50μm.
of data sets according to deﬁned criteria, such as “high” ver-
sus “low” tau expression (as deﬁned in the Results section),
wereanalyzedusingthechi-squaretest.Ratiosofphosphotau
to total tau was calculated using the “sync windows”
and “sync measure” 3D plug ins of ImageJ. Quantitative
comparisons of axonal versus dendritic tau immunolabel
i n t e n s i t yw e r em a d eu s i n gt h e“ M e a s u r eR G B ”p l u g i n .T h i s
was onlydonein “low”tauexpressing ABCsandwas restrict-
ed to sections where both axonal and dendritic proﬁles
were unambiguously present. Unbiased comparison of tau
label intensity between axon proﬁles (which invariably
extended through the entire section) with dendritic proﬁles
which occupied varying proportions of the Z axis was
accomplished by normalizing tau to tubulin levels in each
sample. Quantitation of DAB product for tubulin versus tau
immunolabel ratios in the axons of tau-expressing ABCs and
adjacent axonal proﬁles of similar size was performed on 10
sets of 4 adjacent sections in the obex. Ratios between tau
versus tubulin immunostaining intensity were performed by
comparing the intensity of label between the red and green
color channels on a per voxel basis using the ratio channel
function of Volocity 4.3.
2.5. Colocalization Analyses. Semiquantitative comparisons
of the degree of colocalization to MTs between (a) dendritic
GFP-tau label in low- and high-expressing ABCs (Figure 4)
and (b) markers of high- (tau1, tau5) and low- (9G3) MT-
aﬃnity tauspecies(Figures6and7)wasper f orm edons tacks
using ImageJ “colocalization highlighter” at a common
threshold value. Images in which only the colocalized voxels
are shown (such as was done with the phalloidin label in
someoftheimagesinFigure 7)wereobtainedbysubstituting
the “colocalized points” 8-bit ﬁle generated by colocalization
highlighter for the original channel in the ﬁnal image, which
was produced using the ImageJ plugin “3D Viewer”.
3.Results
3.1. ABC Cytoskeleton. The composition of the somatoden-
dritic and axonal cytoskeleton in lamprey ABCs is typical
of large projection neurons in vertebrate central nervous
systems [8, 47, 48]. Somatodendritic MTs consist of both
stably polymerized and dynamic tubulin in ABCs, especially
inlarge proximaldendrites(5+microns diameter). Totaland
tyrosinated (i.e., recently polymerized) alpha-tubulin levelsInternational Journal of Alzheimer’s Disease 5
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Figure 4: Exogenous tau expression can redistribute and sequester endogenous cytoskeletal elements. (a) Expression of exogenous human
tauinABCsatmoderateexpressionlevelscanresultinthecolocalizationoftauwithendogenousNFswheretauaccumulatesindendritictips.
Note thatNFimmunolabelinnonexpressingABCs decreases toneuropillevelsinthe distaldendrites andthataggregates ofNFimmunolabel
occur only with tau co-localization. The locations of large proximal (1) and smaller distal dendrites (2, 3) are indicated. (b) (1) top: NF
distribution in a large dendrite of an ABC expressing tau at moderate levels is independent of tau (red channel). (2) bottom: signiﬁcant
changes in NF distribution in moredistal dendrites (location2 in (a)),with extensive overlap between the red (tau) andgreen (NF) channels
and relocalization of NFs into punctate deposits (carets) that accumulate in dendritic beads (arrow). (c) shows tau (red) and ﬂuorescently
tagged phalloidin (ﬁlamentous actin, green) distribution. Colocalized voxels can be found in distal dendrites (blue channel). (d) showshigh
magniﬁcation views of co-localized tau (red channel) with NF protein (top), with tubulin (bottom, green channel), and f-actin (bottom,
blue channel) in amorphous aggregates (asterisks) at the distal tips of the ABC shown in (3). Note that the white aggregates shown in the
bottom image (asterisks)are the result ofcolocalizationoftau with both tubulin (DM1A) and f-actin (phalloidin).Scale bars:(a) 50μm, (b)
10μm, (c) 20μm, (d) 5μm.
are highest in such dendrites and both are clearly above
neuropil levels in all but the smallest dendrites. Levels of
acetylated (stably polymerized) tubulin are comparatively
lower, with the largest dendrites staining near neuropil levels
and the smaller ABC dendrites staining below. Tubulin
immunolabel intensity in ABC axons is generally similar to
those seen in the soma and typically were not as strong
as those of dendritic tubulin. NF immunolabel intensity
(LCM3 [44]) is above neuropil levels in large proximal
dendrites, declining distally to below neuropil in the smallest
dendrites (Figure 2). NF staining was stronger in axons than
in somata and dendrites [43, 44], and axonal NF label was
stronger than that of tubulin. This is to be expected given
that NF to MT frequency in large axons such as those of
ABCs is as high as 20:1, and up to 3x higher than that of
small axon proﬁles [46, 49, 50]. Cross reaction of mAbs T46
and Tau7 (not shown) to the relatively well-conserved tau
Ct e r m i n u s[ 51] identiﬁed an axonally targeted endogenous
lamprey MAP (lamprey tau). Lamprey tau is concentrated
in small axons, is relatively low in ABC axons, and is
virtually absent from ABC somata and dendrites (Figure 2)
and so was not considered to be a signiﬁcant factor in the
distribution and MT-binding of exogenous tau species (see
below).
3.2.Expression ofExogenousProteinsinABCs. Previous com-
parisons of the eﬀects of expressing human tau via plasmid
microinjection [8, 9, 45, 52] versus a control proteins (lam-
prey neuroﬁlament NF180) showed that toxicity due to
overexpression is tau speciﬁc. Here we used NF180 and GFP
to control for nonspeciﬁc overexpression eﬀects on MT in-
tegrity and other cytoskeletal changes, especially in the prox-
imal dendrites and axon. Expression of GFP alone resulted
in a relatively even distribution of anti-GFP immunolabel,
while the distribution of exogenous NF180resembled that of
endogenous NF180 (Figure 3).
3.3.DistributionofExogenousTaubetweentheAxonandDen-
drites Is Modulated by Tau Expression Levels in ABCs. We
used the distribution of total exogenous human tau (GFP
tag) relative to that of endogenous tubulin (DM1A) im-
munolabel in proximal dendrites to sort ABCs into “low-
expressing” and “high-expressing” groups (Figures 3 and 5).
In “low-tau” ABCs, the axon and proximal dendrites ex-
hibited the strongest staining in a pattern that was similar
to that of tubulin (Figure 3). This distribution is consistent
with the known function of tau as aMAP and is the expected
pattern if tau is primarily binding directly to MTs. There
was a slight preferential distribution of tau to the proximal
axon relative to proximal dendrites (Figure 3(b)), but this
was only seen at low expression levels in comparisons
between raw GFP-tau levels in WT T24-expressing ABCs
versus GFP alone. The diﬀerence between WT and P301L
tau distribution disappeared when axon:dendrite tau ratios
were normalized to tubulin levels to account for diﬀerences
in z-axis proﬁle dimensions between axons and dendrites.
Preferential axonal staining did not appear to involve the
ability to bind MTs directly, since it was still present with
the S262/356D mutant [50]. By contrast, with “high” tau
expression, tau tended to accumulate in perimembranous
regions of the soma and in distal dendrites (Figures 3(c) and
4). Moreover, tau in high-expressing ABCs was preferentially
localized to dendritic tips and was thus much more distally
located than dendritic tubulin staining. The most striking
diﬀerence between the “low” and “high” distributions of tau
was that in the latter case the areas of highest tau accumu-
lation were devoid of MTs, whereas tau and tubulin were
colocalized with “low” tau expression (Figure 3(c)).6 International Journal of Alzheimer’s Disease
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Figure 5: The state of tau:tubulin colocalization deﬁnes the threshold for tau-induced toxicity in ABCs. (a–c) illustrate the correlation
between tau:tubulin colocalization pattern and neurodegenerative stage [46]. (a) shows a typical example of low (left cell) and high (right
cell)expressioninthesamesection,permittingadirect comparisonofstainingintensity(DAB).Notethatmuchoftheheaviesttaustainingin
the high expressing cell occurs near the plasma membraneinstead of colocalizing with the dendritic cytoskeleton. In particular, the tau label
in the low expressing cell excludes the ventral soma,while this region stains heavily in the high expressing cell. (b) Images of tubulin (green)
and tau (red) immunolabel from proximal dendrites illustrate the criteria used to assign ABCs to “low” and “high” expressing categories as
described in the Methods section. Bottom images show colocalized voxels (colocalizationhighlighter, ImageJ) in the blue channel. With low
tau expression (left andcenter pairs), exogenous tau waslargely colocalized to endogenousMTs in theproximal dendrites, whereas in “high”
tauexpression, much of the tau label wasdistributed in areas devoidoftubulin label. (c) Acomparisonbetween the distribution oftau (GFP
tag, red channel) and tubulin (DM1A, green channel) immunolabel in somatodendritic proﬁles of low-stage (left) and high-stage (right)
ABCs. This clearly shows the relationship between MT saturation state with tau in large proximal dendrites and the stage of tau-induced
degeneration. Note that only the distalmost dendrites of the ABC at the left (swollen, but not beaded) have accumulated high levels of tau,
whereasthecell attheright isexhibiting both dendritic beading andsometausecretion (inset,asterisk).(d)Thecorrelationbetween thelevel
of tau expression and tau-induced degeneration was found to deﬁne the threshold level of tau expression above which tau is toxic to ABCs.
The correlation between ABCs that exhibited “above saturation” levels of tau in proximal dendrites and those exhibiting signiﬁcant beading
and fragmentation of tertiary and quaternary dendrites (Stage 2 or greater of degeneration) was virtually without exception and was highly
signiﬁcant (P   0.001, chi-square test). (e) Quantitative analysis of the eﬀect of tau expression on total, tyrosinated and acetylated tubulin
is shown for the axon (left) and dendrites (right). Tau overexpression had little eﬀect on axonal tubulin levels but signiﬁcantly reduced both
total and tyrosinated tubulin levels and most prominently in normallyMT-rich proximal dendrites (right). No eﬀect was seen for acetylated
tubulin staining in the dendrites (not shown).Scale bars: (b) 10μm, (c) 50μm.International Journal of Alzheimer’s Disease 7
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Figure 6: Accumulation of exogenous tau in the distal dendrites of high tau expressing ABCs is correlated with localized MT loss in distal
dendrites and tau secretion. (a) left: Dendrite showing distal tau accumulation relative to tubulin level as an anti-GFP: DM1A signal ratio
(Volocity), right: a graph summarizing the selective distal dendritic tau accumulation as a function of tau expression level (Bars: SEM). (b)
left: A high-expressing ABC shows extensive tau secretion (asterisks)from morphologically intact dendrites near and immediately proximal
to the POD. The graph to the right shows the relative intensity of tubulin (green, DM1A) versus tau (red, GFP) as a function of distance
from the POD. Intact dendrites immediately proximal to the POD show a combination of recent MT loss and tau accumulation. Tubulin
immunolabel levels were normalized to those in adjacent neuropil as described in the Methods section. Right: Low and high expressing
ABCs were scored (+/) for degeneration and the presence of peridendritic secreted tau deposits. High tau expression (Stage2+) was strongly
correlated with secretion (bottom, asterisks P<0.01, chi-square test).
3.4. High Tau Expression Causes Redistribution of Somatoden-
dritic NFs and f-Actin in ABCs. In low tau-expressing ABCs,
exogenous tau was distinct from that of endogenous NF-180
and ﬁlamentous actin (f-actin) in all parts of the soma and
dendrites, with tau being colocalized with MTs (Figures 4(a)
and 4(b)). High levels of tau expression did not aﬀect this
pattern in the proximal dendrites of high-expressing ABCs;
we found that colocalization of NF protein and f-actin with
tau did occur in the distal dendrites of some high tau-
expressing cells. This was most noticeable at the sites with
the largest accumulations of non-MT-associated tau, which
were typicallyin thevicinity ofthePODor thedendritictips,
depending on the extent of dendritic degeneration. In the
case of endogenous NFs, tau-associated NF180 protein was
displaceddistadofitstypicallocation;thisisreadily apparent
as there are relatively few NFs in the dendrites of non-tau
expressing lamprey neurons [46, 48].
3.5. Tau Distribution and Toxicity in ABCs Is Modulated by
the Saturation of Tau Binding Sites on Endogenous MTs. Low
tau expression is deﬁned as being below or at the level of
tau:MT “saturation” (tubulin is 100% colocalized with tau,
and tau is at least 80% colocalized with tubulin) with all tau
being colocalized with tubulin in ABC proximal dendrites
(Figure 5).Highexpressionisdeﬁnedastauexpressionabove
the level needed to saturate MTs in ABC proximal dendrites.
Low-expressing ABCs nearly always (Figure 5(c)) show low-
stage (1 or 1.5) tau-induced degeneration. This deﬁnition is
consistent with the staging scheme of tau-induced degen-
eration described in an earlier study [52]i nw h i c hs t a g e
1 was deﬁned by the ﬁlling of dendritic proﬁles with even
tau label, and higher levels of tau expression (stages 2-
3) were characterized by the distal to proximal extent of
dendritic degeneration. ABCs staged as “high expressing”
(i.e., stage 2 and above) by this method were almost perfectly
cosegregated with those scored as having proximal dendrites
“above saturation” (Figure 5(c)).
3.6. Tau Redistribution with High Expression Is Correlated
with Microtubule Loss and Dendritic Degeneration. The most8 International Journal of Alzheimer’s Disease
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label is visible). Right image: Section is labeled for low-aﬃnity (9G3, red channel) and high-aﬃnity (Tau 1, green channel) tau. Note that
there is considerable colocalization near the central MT bundle (blue channel), which is consistent with the dynamic nature of dendritic
MTs. Scale bar: 10μm.
dramatic eﬀect of high tau expression was to induce tau ac-
cumulation in distal dendritic tips (Figures 3(c) and 5)[ 8,
9, 18]. This was accompanied by the loss of tubulin label
that was most evident with tyrosinated tubulin in dis-
tal dendrites (Figures 5(e) and 6). By contrast, the level
of tau expression had little eﬀect on axonal tubulin levels
(Figure 5(e)). The distal dendritic tau accumulations seen
with high tau expression were always associated with den-
driticdegeneration(Figure 3(c)),whichwasconﬁrmedwhen
tau:tubulin ratios were calculated for GFP/DM1A immuno-
labeled sections using the ratio channel facility in Volocity
(Figure 6(a))and whenratiomeasurementsweretakenman-
ually (Figure 6(b)). We found that the majority of sites at the
POD (59%) showed tau:tubulin ratios of 8:1 or higher, with
24% at 12:1 or higher, whereas 82% of sites sampled 20–
50 microns away from the POD showed ratios of under 7:1.
Moreover, 90% of the sites with the highest tubulin intensity
readings (i.e., with readings above neuropil immunostaining
levels in the distal dendrites) were beyond 25 microns
from the POD and had tau:tubulin ratios of 7:1 or below,
while all of the sites with the highest tau readings were
located at or distal to the POD (Figure 6). This was in
close agreement with the Volocity ratio results and strongly
indicates that some mechanistic connection exists between
tau accumulation in the distal dendrites and localized MT
loss and degeneration there.
3.7. Distally Transported Tau Is Disproportionately Phos-
phorylated at the 9G3 and 12E8 Sites. We found that tau
phosphorylation state in distal dendritic accumulations is
inversely correlated with respect to tubulin immunostaining
levels and thus presumably not MT-associated (Figure 8).
The tau in such accumulations is enriched in phosphotau
species that are either incapable of binding (12E8+ tau [53–
55]) or are not currently bound to MTs (9G3—see Figure 7).
By contrast, markers identifying poorly phosphorylated tau
with high MT aﬃnity (Tau1, Tau5, Tau12) was localized to
MT-rich regions (i.e., large dendrites), with mAbs marking
proline-directed phosphorylation that reduces but do not
abolish tau:MT binding (AT180, PHF-1 and AT8) showing
an intermediate pattern (Figure 8). High-MT-aﬃnity tau
was largely colocalized with MTs in ABC dendrites and
accumulated minimally at the POD, while 9G3+ tau or tau
phosphorylated at KXGS sites in the MTBRs (12E8+ tau)
was localized to either the POD itself or to a ventrolateral
somatic location near the bases of large dendrites. Proline-
directed phosphoepitopes(i.e.,AT8, AT180, PHF1)were also
more concentrated at the POD than was total (GFP+) tau
(Figure 5(c)), but this tendency was less pronounced than
with 9G3 and 12E8 (Figure 8).
3.8.TauPhosphorylatedatthe9G3and12E8SitesIsAssociated
with Fyn- and LC3-Containing Vesicles near Secretion Sites
in ABC Dendrites. In earlier studies, we showed that distal
dendrites of high-expressing ABCs become strongly tau
positive [9] and ﬁlled with vesicular inclusions [8, 18].
Some of the tau accumulated at dendritic tips or the POD
becomes transiently immunopositive for 9G3 (marking tauInternational Journal of Alzheimer’s Disease 9
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Figure 8: Evidence for the transport and distribution of hyperphosphorylated tau with low MT binding aﬃnity into distal dendrites. (a)
Examples of somatodendritic proﬁles from ABCs expressing high tau levels immunolabeled with phosphospeciﬁc Abs to epitopes on human
tau (described in Figure 7) that identify low,medium, and high degrees of tau associationwith MTs. The green channel showsimmunolabel
Abs identifying tau with low (9G3, 12E8), medium (AT180, PHF1), and high (Tau1, Tau5, Tau12) MT aﬃnity showing characteristically
diﬀerent distributions relative to the PODandto “total” taudistribution asshownby anti-GFP tag immunolabel(red channel ofall images).
Markers of non-MT-associated tau (9G3 and 12E8, right panels) are the most concentrated at the POD (line) and the least associated with
MT-rich proximal dendrites (asterisks). By contrast, markers of dephosphorylated tau (e.g., Tau1—bottom left panel) are less concentrated
atthePODandarelargelycodistributed withtubulin (topleft),AT180andPHF1,whichmarkintermediatestatesofMTaﬃnityandshowan
intermediate distribution pattern. (b) Quantitation of the relationships illustrated by the sections shown in (a). Tau immunolabel intensity
was normalized to the level seen at the POD for each antibody in each section examined and the relative intensity of immunolabel shown.
Diﬀerences in distribution between proximal dendrites the POD and degenerating dendrites distal to the POD were highly signiﬁcant for
each antibody examined (all P values < 0.005, Student’s t-test). Markers of low-aﬃnity tau (green) were signiﬁcantly lower than medium-
(blue) and high- (tan) MT-aﬃnity markers in proximal dendrites (P<0.01 and 0.001, resp.), whereas all tau markers declined to a level
signiﬁcantly below that of the POD in degenerating distal dendrites (all P values < 0.001). Bars show standard error. (c) A schematic
diagram summarizing the relationship between the distribution of tau with low (9G3, 12E8), medium (AT180, PHF1), and high (Tau1,
Tau5, Tau12) MT aﬃnity illustrated in (a) and analyzed in (b). Scale bars: (a) 100μm.
phosphorylation at Y18 by srk-family tyrosine kinases) and
may undergo secretion to the extracellular space [43]. In this
study, we characterized these inclusions in more detail by
immunolabeling sections through tau-secreting ABCs with
multiple anti-tau antibodies (Figures 7 and 8)t o g e t h e rw i t h
A b st os p e c i ﬁ cv e s i c u l a rm a r k e r s ,a sw e l la st h eﬂ u o r e s c e n t l y
labeledf-actin markerphalloidin.Wefound thattau-positive
vesicular proﬁles at the surfaces of intact dendrites near the
POD in ABCs expressing high levels of tau were colocalized
with either non-MT-associated tau epitopes (9G3, 12E8)10 International Journal of Alzheimer’s Disease
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Figure 9: The mechanism of tau-induced dendritic degeneration in ABCs. (a) Schematic summarizingthe hypothesized sequence of events
leading to tau-induced degeneration in ABC dendrites. Low-level exogenous tau expression (1) does not saturate the tau:tubulin binding
sites on dendritic MTs, permitting all exogenous tau to bind directly to dendritic MTs (green arrows) and remain poorly phosphorylated
and nontoxic. (2) In ABCs expressing enough exogenous tau to saturate existing MTs, excess tau becomes phosphorylated at the 9G3 and
12E8 sites and associated with traﬃcking vesicles. These are transported distally to and accumulate in the relatively MT-poor dendritic tips,
where they induce degeneration, possibly by being secreted to form toxic extracellular deposits. (3) The consequent increased intracellular
Ca2+, MT destabilization, misdistribution of mitochondria, and cytoskeletal aggregation become self-perpetuating (4, red arrows), driving
progressive dendritic degeneration(black).(b) ColocalizationofMT lossandnon-MT-associatedtauaccumulation.A z-axisreconstruction
of a dendrite (left) containing a bundle of MTs along which tau was being transported distally (1–5) and accumulating (6–11) at the POD.
The distribution of total tau (GFP tag, red) and non-MT-associated tau (9G3, blue) is shown versus tubulin (green). Numbers correspond
to the sites in the original stack (left) chosen for cross-sectional views (right and bottom). Note that MTs (asterisks,3) rapidly become more
saturated with tau between sections 1 and 3. Above the tau-MT saturation point (3, caret), the MT bundles lose tubulin label over a very
short distance (black arrows, 4 and 5). Scale bar: 2μm.
and/or markers of vesicular organelles (Figures 9 and 10). At
siteswhere secretion was ongoing,many butnotall 9G3tau+
vesicles were colocalized with the srk family tyrosine kinase
fyn, which can be considered a dendritic endosome marker
[56, 57], with 12E8-positive tau being similarly distributed
(not shown). When compared to markers of high-MT-
aﬃnitytau(T au5,T au12),theGFPtagfusedtothetauamino
terminus also selectively identiﬁed exocytotic proﬁles at sites
of focal secretion (Figure 10).
4.Discussion
The misprocessing of tau is a key event in neurodegenerative
tauopathies and is typically not associated with MTs. How-
ever, the details of the toxicity-associated tau misprocessing
pathway in the absence of MT binding are still very poor-
ly understood. We employed overexpression as a means of
generating non-MT-associated tau in ABCs in order to
characterize this pathway and its relationship to tau-induced
degeneration in a high-resolution cellular model in situ.
We show that the expression of exogenous tau causes a
dose-dependent loss of somatodendritic MTs that is spa-
tiotemporally correlated with tau-induced degeneration. We
conﬁrm earlier ﬁndings in the lamprey system and else-
where that tau colocalizes with certain vesicular organelles,
especially when phosphorylated at Y18 [18, 36]. Our results
indicate that the saturation of dendritic MTs by exogenous
human tau accounts for the changes in tau distribu-
tionand phosphorylation seenbetweenABCsexpressing low
and high levels of tau. Tau expression above this threshold
is correlated with degeneration patterns that account for
all of the characteristics of tau-induced toxicity observed in
this model (and others to our knowledge) so far. We also
conducted the ﬁrst detailed morphological characterization
of tau secretion from CNS neurons in an in situ tauopathy
model and present evidence that tau secretion occurs viaInternational Journal of Alzheimer’s Disease 11
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Figure 10:High-resolutionconfocalimagesof“focal”tausecretion fromABCs.(a)Highmagniﬁcationimagingofsurface rendered (ImageJ
3D Viewer) images of dendrites near the POD show signiﬁcant colocalization between fyn and tau (left) in what appear to be exocytotic
proﬁles (yellow). Active tau secretion via exocytosis can be identiﬁed in high-magniﬁcation confocal images of the surfaces of dendrites
proximal to the POD in conjunction with the secretion of fyn-positive vesicles. Selective inclusion of 9G3 in secreted tau can be seen in
exocytosing proﬁles from intact dendrites near the POD (right). (b) The autophagy marker LC3 undergoes secretion from ABC dendrites
in a process that appears largely independent of tau (left), but higher resolution images show low levels of tau found in LC3+ vesicles
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involve cosecretion of tau and fyn. (f) The images shown in (a–d) suggest that multiple unconventional secretion pathways are involved in
“focal” tau secretion from ABC dendrites. These includethedirect sheddingofmicrovesiclescontainingraftproteins (left),thegenerationof
multivesicularbodies viaraft“patching” andendocytosis,followedbyMVBexocytosis andexosomerelease(center),andarecently identiﬁed
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an unconventionalmechanism with characteristics of micro-
vesicle and exosome-mediated routes. These events are sum-
marizedinFigures9and10,andtheirrelevancetoandimpli-
cations for tau pathobiology in human disease are discussed
below.
4.1. Distribution of Exogenous Tau in ABCs. The overexpres-
sion of both WT and tauopathy mutant tau in ABCs in
most cases produces phosphorylated tau accumulation in
dendrites, as reported previously [8, 9, 18, 41]. While there
did appear to be some preferential distribution of exogenous
tau to the axon at relatively low levels of overexpression in
ABCs, this eﬀect was slight and was apparently not related
to the preferential association of tau with axonal versus
dendritic MTs. Moreover, even this slight preference was lost
with relatively moderate levels of overexpression, a pattern
similar to that seen with early murine transgenic models
[58, 59]. This is consistent with reports that active targeting
of tau to the axon occurs mainly at the mRNA rather than
the protein level [60, 61]a n dw i t hr e p o r t st h a tt a um a yb e
slightly overexpressed in non-AD human tauopathies [62].
We, therefore, propose that tau overexpression in ABCs re-
creates the circumstances needed for tau toxicity (e.g., tau
hyperphosphorylation, tau cleavage) simply by exceeding
the tau-binding capacity of endogenous dendritic MTs. The
relative insensitivity of axonal MTs to the destabilizing eﬀect
oftauoverexpressionsuggeststhattheprimary eﬀectisagain
of a toxic function in the dendrites rather than the loss of
normal MT stabilization axon in the axon.
4.2. MT Saturation and the Centrifugal Redistribution of
Non-MT-Associated Tau. In the ABC model, the occurrence
of tau-induced dendritic MT loss, vesicular tau, and tau
secretion at the POD appear to be mechanistically related
given that the POD is also the site of both the highest
focal tau secretion levels and of the sharpest decrease in
dendritic tubulin levels (Figure 5(b)). Our ﬁndings are also
consistent with studies showing tau redistribution to MT-
poor regions of the cell whenever it is present in excess of
available MT tau binding capacity, whether this occurs by
overexpression or by some disease-related mechanism that
limits tau:MTbinding [63].The limited tau binding capacity
of dendritic MTs for tau in ABCs thus appears to serve
as a threshold above which excess tau is processed by an
alternative, toxicity-generating pathway. Moreover, since tau
has been shown to modulate the activity of MT-associated
motor proteins that mediate dendritic transport [64, 65],
often in a disease-speciﬁc [66] or overexpression-induced
[67] manner, it seems likely that toxicity resulting from tau
accumulation at localized dendritic loci may have relevance
to the pathogenesis of human tauopathies, which typically
feature abnormal somatodendritic phosphotau accumula-
tion.
4.3. A Signiﬁcant Proportion of Non-MT-Bound Tau Is Vesicle
Associated and Is Associated with Tau Toxicity. Hyperphos-
phorylated, non-MT-associated tau is widely considered to
be the agent of neurodegeneration in human tauopathies,
although little is known about its underlying toxicity mech-
anism. Here we conﬁrm other demonstrations in the ABC
model that a tight correlation exists between 9G3 phospho-
rylation and localized tau-induced neurodegeneration [41]
(Figures 7 and 9), and that tau overexpression is associated
with vesicle accumulation in ABC distal dendrites [8, 18].
Ourobservationsshow thatthephosphorylated tauaccumu-
lating where dendritic MTs are being lost in ABC dendrites
is largely vesicle associated and that some of these vesicles
resembleendosomesand/orautophagosomesintheirgeneral
appearance and colocalization with endosome (fyn) and
autophagosome (LC3) markers (Figure 10). Moreover, this
toxic, vesicle-associated tau accumulates selectively in MT-
poor regions that are adjacent to more proximal dendritic
segments containing organized MT bundles (Figure 9), sug-
gesting (1) that it is translocated via MT-mediated transport
in ABC dendrites and (2) that its accumulation is both the
cause and the consequence of localized MT destabilization.
We propose that abnormal tau involvement in the formation
oftraﬃckingvesiclesoriginating fromtheplasma membrane
and/or the autophagy pathway in the absence of MT
association cause the accumulation of 9G3/12E8, positive
tau, which in turn destabilizes nearby MTs via an as yet
unknown mechanism. This could account for the selective
MT lossassociated with neuroﬁbrillary pathologyin humans
[1, 2, 68, 69] and suggests that hyperphosphorylated, non-
MT-associated tau may be bound to vesicles that are
transported within the cell via MT-mediated mechanisms in
human tauopathies. This idea has been little explored but
is consistent with much of the relevant human tauopathy
literature and could add a new dimension to our conception
of abnormal tau processing in neurodegenerative disease.
Neuropathologicalstudiessuggestthat hyperphosphorylated
tau may oligomerize into granular and ultimately ﬁbrillar
deposits and that an unknown element in this sequence of
events mediates tau toxicity [3, 68, 69]. This is supported
by demonstrations that “pretangle” deposits of granular,
hyperphosphorylated tau precede NFT formation in murine
models [70, 71] and appear to do so in humans [68, 69].
However, interactions between tau and membrane/vesicle-
associated proteins are also associated with and may mediate
aspects of neuroﬁbrillary disease. Tau oligomerization can
be driven by fatty acids in vitro [72, 73], while NFT
formation is associated with membranous organelles in
vivo [74, 75]. Misprocessed tau has been associated with
abnormalities in several types of vesicular organelle in
AD and tauopathy models, including the Golgi apparatus
[39], lysosomes [76–78], autophagosomes [76, 79–81], and
most recently exosomes [82]. The last two are of particular
interest in light of our ﬁndings here that vesicular tau is
colocalized with the lipid raft-associated tyrosine kinase fyn,
which itself is both required for extracellular beta-amyloid-
mediated toxicity via tau [83, 84] and is mislocalized in AD
[85, 86]. Since fyn has been identiﬁed in exosomes (along
with other signal transduction associated kinases) [87], it
appears that interaction with and phosphorylation of tau at
the 9G3 site by fyn may be a key feature of both secretion
and toxicity-associated tau processing. Fyn activation during
signal transduction typically causes the oligomerization andInternational Journal of Alzheimer’s Disease 13
endocytosis of downstream elements [88]a n dt a r g e t sa t
least some oligomerized targets of fyn phosphorylation to
exosomes [89, 90], a process which appears to be highly
analogous to what we see with tau in the ABC system.
Similarly, the involvementof the (macro)autophagy pathway
of protein turnover in AD has long been known [79–81,
91], and this has more recently been extended to non-AD
tauopathies [77–79], where it now appears to play a largely
disruptive role in autophagic protein turnover mechanisms
that may well exacerbate tau toxicity in these diseases
[80]. The association of non-MT-associated tau with fyn or
LC3-positive is consistent with microvesicular or exosomal
secretion, as discussed below.
4.4. Possible Mechanisms of Dendritic Tau Secretion. In a pre-
vious study, we found that tau secretion from ABC dendrites
requires elements in both the tau N-terminal and MTBR
domains and inferred that such secretion is transient, ﬁrst
appearing before the onset of overt degeneration and ending
before complete fragmentation of the dendrite occurs [41].
While these results showed tau secretion to be an active
biological process rather than a passive release of tau from
autolyzing neurons, they gave little indication as to the
mechanism of tau secretion and why it is spatiotemporally
correlated with dendritic degeneration in ABCs. The present
study yields speciﬁc indications as to the secretion mecha-
nism by (a) correlating MT loss and the distribution of non-
MT-associated tau with “focal” secretion from ABC den-
drites just before the onset of dendritic degeneration and by
characterizing the (b) morphology of exocytotic proﬁles and
(c) the phosphorylation state and proteins colocalized with
the secreted tau. In particular, we show that at least some tau
secretion is associated with fyn-positive, endosome-like vesi-
cles in which tau has been phosphorylated at the site (Y18)
characteristically phosphorylated by fyn, and that another
subset of tau-containing vesicles is colocalized with the
autophagymarker LC3, which also appears to be exocytosed.
Itisnoteworthy that,in normal autophagy,LC3 israrely seen
among the exocytosed proteins due to its exposure to lysoso-
mal hydrolases [80]. However, tau appears to interfere with
autophagygenerallyintauopathiesandwiththeacidiﬁcation
of autolysosomes in particular. A third subset of externalized
tau appears to be morphologically dissimilar from vesicle
exocytosis, suggesting a mechanism akin to plasma mem-
brane blebbing [92] or the “membrane shedding” seen with
the unconventional secretion of galectin-1 [90]( Figure 10).
A more general issue relevant to both dendritic tau secretion
and toxicity was raised by a recent study by Ittner et al.
[93] which showed that dendritic localization of tau can
selectively mediate Abeta toxicity. This is consistent with the
generallydendrite-speciﬁctoxicityobservedinthisstudyand
suggeststhattheabnormaljuxtapositionoftauanddendrite-
speciﬁc signal transduction mechanisms might play a role in
both tau-mediated toxicity and tau secretion.
5.Conclusion
Little is currently known about exactly how non-MT-asso-
ciated tau becomes cytotoxic en route to its oligomerization
and polymerization into neuroﬁbrillary deposits in human
tauopathies other than that (a) tau becomes a substrate
f o rt y r o s i n ea sw e l la ss e r i n e / threonine kinases and (b) tau
undergoes progressive amino and carboxyl terminal cleavage
at some point in the process. Here we show that, when
tau becomes disassociated from MTs by virtue of overex-
pression, it is processed via a novel pathway that generates
localized cytotoxicity manifested by MT loss and dendritic
degeneration that is preceded by the secretion of some of
the misprocessed tau via an unconventional mechanism that
involves elements of both exosome and autophagy pathways.
Tau misprocessing in ABCs involves (1) the interaction of
tau with elements in the subcortical cytoskeleton and its
phosphorylation of tau at characteristic AD-related sites, (2)
the MT-mediated transport of hyperphosphorylated tau in
association with vesicles and their accumulation in distal
dendrites, and (3) the progressive MT loss and dendritic dys-
function in the immediate vicinity of these deposits, which
may be exacerbated by localized secretion followed by extra-
cellularly mediated toxicity. While the roles played by these
events in the generation of neuroﬁbrillary deposits, toxic tau
oligomers, and the interneuronal spread of tau lesions are
still unclear, our results lay the ground for acquiring a more
detailed understanding of the role played by tau misprocess-
ing in the cytopathogenesis of neurodegenerative disease.
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